Acute coronary syndromes in women: Is treatment different? Should it be?

Current Cardiology Reports

Volumn 6, Issue 4, 2004, Pages 243-252

  Bennett, Susan K ^a   Redberg, Rita F ^b  

^a GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MALE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PREVALENCE; SEX DIFFERENCE; ST SEGMENT ELEVATION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 5444249331     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0071-2     Document Type: Article

References (63)

1. Wizemann T, Pardue M: Exploring the Biological Contributions to Human Health: Does Sex Matter? Committee on Understanding the Biology of Sex and Gender Differences, Board on Health Sciences Policy, Institute of Medicine. Washington, DC: National Academy Press; 2001.
2. American Heart Association: Heart Disease and Stroke Statistics - 2004 Update. Dallas: American Heart Association; 2003.
3. Mosca L, Appel L, Benjamin E, et al.: Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109: 672-692.
4. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308: 81-106.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction (ISIS-2). Lancet 1988, ii: 349-360.
6. Freemantle N, Cleland J, Young P, et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999, 318: 1730-1737.
7. The Beta-Blocker Pooling Research Group: The Beta-Blocker Pooling Project (BBPP): subgroup findings for randomized trials in post infarction patients. Eur Heart J 1988, 9: 8-16.
8. Sleight P: Beta-blockade early in acute myocardial infarction. Am J Cardiol 1987, 60: 6A-10A.
9. Roberts R, Rogers W, Mueller H, Lambrew, et al.: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Circulation 1991, 83:422-437.
10. Silvet H, Spencer F, Yarzebski J, et al.: Communitywide trends in the use and outcomes associated with beta-blockers in patients with acute myocardial infarction. Arch Intern Med 2003, 163: 2175-2183.
11. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation 1998, 97; 2202-2212.
12. Flather M, Yusuf S, Kober L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000, 355: 1575-1581.
13. Pfeffer M, McMurray J, Velazquez E, et al.: Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349: 1893-1906.
14. Burwen D, Galashu D, Lewis J, et al.: National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999. Arch Intern Med 2003, 163: 1430-1439.
15. Fibrinolytic Therapy Trialists' (FIT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994, 343: 311-322.
16. Weaver WD, White H, Wilcox R, et al.: Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA 1996, 275: 777-782.
17. White H, Barbash G, Modan M, et al.: After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality as men except for a higher incidence of hemorraghic stroke. Circulation 1993, 88[Part 1]: 2097-2103.
18. Gore J, Granger C, Simoons M, et al.: Stroke after thrombolysis; mortality and functional outcomes in the GUSTO-1 trial. Circulation 1995, 92: 2811-2818.
19. Berkowitz S, Granger C, Pieper K, et al.: Incidence and predictors of bleeding after contemporary thrombolytic therapy for acute myocardial infarction. Circulation 1997, 95: 2508-2516.
20. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators: Single-bolus tenecteplase compared to front-loaded alteplase in acute myocardial infarction. Lancet 1999, 354: 716-722.
21. Wallentin L, Lagerqvist B, Husted S, et al.: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial Lancet 2000, 356: 9-16.
22. Mehta S, Eikelboom J, Yusuf S: Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 2000, 356: 449-454.
23. Eagle K, Goodman S, Avezum A, et al.: Practice variation and missed opportunities for reperfusion in st-segment elevation myocardial infarction: finding from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002, 359: 373-377.
24. Grace S, Abbey S, Bisaillon S, et al.: Presentation, delay and contraindication to thrombolytic treatment in females and males with myocardial infarction. Womens Health Issues 2003, 13: 214-221.
25. Zijlstra F, Patel A, Jones M: Clinical characteristics and outcome of patients with early (< 2h), intermediate (2-4 h) and late (> 4 h) presentation treated by primary angioplasty or thrombolytic therapy Eur Heart J 2002, 23: 550-557.
26. Jacobs A, Johnton J, Haviland A, et al.: Improved outcomes for women undergoing contemporary percutaneous intervention. J Am Coll Cardiol 2002, 39: 1608-1614.
27. Welty F, Lewis S, Kowalker W, Shubrooks S: Reason for higher in-hospital mortality > 24 hours after percutaneous transluminal coronary angioplasty in women compared to men. Am J Cardiol 2001, 88: 473-477.
28. Harrold L, Esteban J, Lessard D, et al.: Narrowing gender differences in procedure use for acute myocardial infarction. J Gen Intern Med 2003, 18: 423-431.
29. Gan S, Beaver S, Houck P, et al.: Treatment of acute myocardial infarction and 30-day mortality among men and women. N Engl J Med 2000, 343: 8-15.
30. Chandra N, Ziegelstein R, Rogers W, et al.: Observations of the treatment of women in the United States with myocardial infarction. Arch Intern Med 1998, 158: 981-988.
31. Roger V, Farkouh M, Weston S, et al.: Sex differences in evaluation and outcome of unstable angina. JAMA 2000, 283: 646-652.
32. Cannon C, Weintraub W, Demopoulos L: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344: 1879-1887.
33. Stone G, Grines C, Browne K, et al.: Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction Am J Cardiol 1995, 75:987-992.
34. Vakili B, Kaplan R, Brown D: Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001, 104: 3034-3038.
35. Grines C, Cox D, Stone G, et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999, 341: 1949-1956.
36. Lansky A: Outcomes of percutaneous and surgical revascularization in women. Prog Cardiovasc Dis 2004, 46: 305-319.
37. Antoniucci D, Valenti R, Moschi G, et al.: Sex-based differences in clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol 2001, 87: 289-293.
38. Keeley E, Boura J, Grines C: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361: 13-20.
39. Holmes D, Leon M, Moses J, et al.: Analysis of 1-year clinical outcomes in the SIRIUS trial. Circulation 2004, 109: 634-640.
40. Saia F, Lemos P, Lee C-H, et al.: Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction. Circulation 2003, 108: 1927-1929.
41. Boersma E, Harrington R, Moliterno D, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359: 189-198.
42. Cho L, Topol E, Balog C, et al.: Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender J Am Coll Cardiol 2000, 36: 381-386.
43. Eikelboom J, Anand S, Malmberg K, et al.: Unfractionated heparin and low-molecular weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000, 355: 1936-1942.
44. Cohen M, Demers C, Gurfinkel E, et al.: A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337: 447-452.
45. Antman E, McCabe C, Gurfinkel E: Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999, 100: 1593-1601.
46. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358: 605-613.
47. Wallentin L, Goldstein P, Armstrong P: Efficacy and safety of tenecteplase in combination with the low-molecular weight heparin enoxaparin or unfractionated heparin in the prehospital setting. Circulation 2003, 108: 135-142.
48. Wallentin L: ASSENT-3: one-year follow-up; 2002. 18th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Chicago, IL: November 16, 2002.
49. The Direct Thrombin Inhibitors Trialists' Collaborative Group: Direct thrombin inhibitors in acute coronary syndroms: principal results of a meta-analysis based on individual patient's data Lancet 2002, 359: 294-302.
50. The Hirulog and Early Perfusion or Occlusion (HERO)-2 Trial Investigators: Thrombin-specific anticoagulation with bilvalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358: 1855-1863.
51. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to asprin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345: 494-502.
52. Mehta S, Yusuf S, Peters R, Bertrand M: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoin percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358: 527-533.
53. Fox K, Poole-Wilson P, Henderson R, et al.: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA-3 randomised trial. Lancet 2002, 360: 743-751.
54. FRagmin and Fast Revascularization during InStability in Coronary Artery Disease (FRISC II) Investigators: Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999, 354: 708-715.
55. Woods S, Noble G, Smith JM, Hasselfeld K: The influence of gender in patients undergoing coronary artery bypass surgery: an eight-year prospective hospitalized cohort study. J Am Coll Surg 2003, 196: 428-434.
56. Vaccarino V, Abramson J, Veledar E, Weintraub W: Sex differences in hospital mortality after coronary artery bypass surgery Circulation 2002, 105: 1176-1181.
57. Hogue C, Barzilai B, Pieper K, et al.: Sex differences in neurologic outcomes and mortality after cardiac surgery Circulation 2001, 103: 2133-2137.
58. Stamou S, Jablonski K, Pfister A, et al.: Stroke after conventional versus minimally invasive coronary artery bypass. Ann Thorac Surg 2002, 74: 394-399.
59. Vaccarino V, Zhen QL, Kasl S, et al.: Gender differences in recovery after coronary artery bypass surgery. J Am Coll Cardiol 2003, 41; 307-314.
60. Vaccarino V, Parsons L, Every N, et al.: Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999, 341: 217-225.
61. MacIntyre K, Stewart S, Capewell S, et al.: Gender and survival: a population-based study of 201,114 men and women following a first myocardial infarction. J Am Coll Cardiol 2001, 38: 729-735.
62. Chang W, Kaul P, Westerhout C, et al.: Impact of sex on long-term mortality from acute myocardial infarction vs. unstable angina. Arch Intern Med 2003, 163: 2476-2484.
63. King K, Ghali W, Faris P, et al.: Sex differences in outcomes after cardiac catheterization. JAMA 2004, 291 1220-1225.